Recombinant Phyllomedusa burmeisteri Phylloseptin Bu-2
Description
Discovery and Origin
Phylloseptin-PBa2 was identified through cDNA library cloning and mass spectrometry sequencing of Phyllomedusa burmeisteri skin secretions . Key steps included:
-
Shotgun Cloning: A degenerate primer and NUP primer were used to isolate preprophylloseptin cDNA, revealing a 19-amino acid mature peptide with a C-terminal amidation .
-
Synthesis: Solid-phase peptide synthesis (SPPS) and RP-HPLC purification confirmed its sequence: FLSLIPHAISAVSALAKHL-NH2 .
Antimicrobial Activity
Phylloseptin-PBa2 demonstrates selective activity against Gram-positive bacteria and fungi:
-
Mechanism: Disrupts bacterial membranes via electrostatic interactions, confirmed by Sytox Green uptake assays .
-
Stability: Retains activity in serum and salt conditions, unlike many natural AMPs .
Anticancer Activity
Phylloseptin-PBa2 shows cytotoxicity against cancer cell lines with minimal effects on normal cells:
| Cell Line | IC50 (μM) | Reference |
|---|---|---|
| MB435s (Breast adenocarcinoma) | 25 | |
| H460 (Lung carcinoma) | 30 | |
| HMEC-1 (Normal endothelial) | >100 |
-
Selectivity: Higher therapeutic index compared to traditional chemotherapeutics due to low haemolytic activity .
Haemolytic Activity
Phylloseptin-PBa2 exhibits minimal haemolysis at therapeutic concentrations:
This low toxicity profile enhances its potential for systemic applications .
Mechanism of Action
-
Membrane Disruption: Lysine residues enhance binding to negatively charged cancer/bacterial membranes, causing pore formation and cell lysis .
-
Anti-Biofilm Activity: Eradicates preformed Staphylococcus aureus biofilms at 2× MIC .
-
Apoptosis Induction: Triggers mitochondrial membrane depolarization in cancer cells .
Therapeutic Potential
Phylloseptin-PBa2’s advantages include:
-
Broad-Spectrum Activity: Targets antibiotic-resistant pathogens (e.g., MRSA) and multidrug-resistant cancers .
-
Scalable Production: SPPS enables cost-effective synthesis for clinical trials .
-
Synergy: Combines with conventional antibiotics to reduce required doses and resistance risk .
Future Directions
Current research focuses on:
